UCOMB-real life data: treatment strategies for chronic urticaria patients with comorbidities

References

• Gonçalo M, Gimenéz-Arnau A, Al-Ahmad M, et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2020;184(2):1–6. doi: 10.1111/bjd.19561.
   Web of Science ®Google Scholar
• Fricke J, Ávila G, Keller T, et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy. 2020;75(2):423–432. doi: 10.1111/all.14037.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734–766. doi: 10.1111/all.15090.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Maurer M. Omalizumab for the treatment of chronic urticaria. Expert Rev Clin Immunol. 2015;11(2):171–180. doi: 10.1586/1744666x.2015.993971.
   PubMed Web of Science ®Google Scholar
• Vena GA, Maurer M, Cassano N, et al. Alternative treatments for chronic spontaneous urticaria beyond the guideline algorithm. Curr Opin Allergy Clin Immunol. 2017;17(4):278–285. doi: 10.1097/aci.0000000000000372.
   PubMed Web of Science ®Google Scholar
• Rutkowski K, Wagner A, Jui-Lin Choo K, et al. “Omalizumab plus”: combining omalizumab with immunosuppression for treatment of refractory chronic urticaria: a multicenter UK series. J Allergy Clin Immunol Pract. 2021;9(3):1400–1401. doi: 10.1016/j.jaip.2020.10.056.
   PubMed Web of Science ®Google Scholar
• Maoz-Segal R, Levy T, Haj-Yahia S, et al. Combination therapy with omalizumab and an immune-suppressive agent for resistant chronic spontaneous rrticaria - A real-life experience. World Allergy Organ J. 2020;13(8):100448. doi: 10.1016/j.waojou.2020.100448.
   PubMed Web of Science ®Google Scholar
• Staubach P, Mann C, Peveling-Oberhag A, et al. Epidemiology of urticaria in german children. J Dtsch Dermatol Ges. 2021;19(7):1013–1019. doi: 10.1111/ddg.14485.
   Google Scholar
• Papapostolou N, Xepapadaki P, Katoulis A, et al. Comorbidities of chronic urticaria: a glimpse into a complex relationship. Front Allergy. 2022;3:1008145. doi: 10.3389/falgy.2022.1008145.
   PubMedGoogle Scholar
• Zbiciak-Nylec M, Wcisło-Dziadecka D, Kasprzyk M, et al. Overweight and obesity may play a role in the pathogenesis of chronic spontaneous urticaria. Clin Exp Dermatol. 2018;43(5):525–528. doi: 10.1111/ced.13368.
   PubMed Web of Science ®Google Scholar
• Vollono L, Piccolo A, Lanna C, et al. Omalizumab for chronic spontaneous urticaria in “complex” patients: data from real-life clinical practice. Drug Des Devel Ther. 2019;13:3181–3186. doi: 10.2147/dddt.S214307.
   PubMed Web of Science ®Google Scholar
• Ke X, Kavati A, Wertz D, et al. Real-World characteristics and treatment patterns in patients with urticaria initiating omalizumab in the United States. J Manag Care Spec Pharm. 2018;24(7):598–606. doi: 10.18553/jmcp.2018.24.7.598.
   PubMed Web of Science ®Google Scholar
• Giménez-Arnau A, Velasco M, Armario Hita JC, et al. Omalizumab: what benefits should we expect? Eur J Dermatol. 2016;26(4):340–344. doi: 10.1684/ejd.2016.2809.
   PubMed Web of Science ®Google Scholar
• Sánchez J, Alvarez L, Cardona R. Cyclosporine and omalizumab together: a new option for chronic refractory urticaria. J Allergy Clin Immunol Pract. 2020;8(6):2101–2103. doi: 10.1016/j.jaip.2020.02.012.
   PubMed Web of Science ®Google Scholar
• Vena GA, Cassano N, Colombo D, et al. Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol. 2006;55(4):705–709. doi: 10.1016/j.jaad.2006.04.078.
   PubMed Web of Science ®Google Scholar
• Salman A, Ergun T, Gimenez-Arnau AM. Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study. J Dermatolog Treat. 2020;31(2):204–209. doi: 10.1080/09546634.2019.1589639.
   PubMed Web of Science ®Google Scholar
• Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101–109. doi: 10.1016/j.jaci.2013.05.013.
   PubMed Web of Science ®Google Scholar
• Hayama K, Fujita H, Asai-Sato M, et al. Successful treatment of intractable chronic spontaneous urticaria with omalizumab in a patient with ovarian cancer. Eur J Dermatol. 2021;31(1):100–101. doi: 10.1684/ejd.2020.3959.
   PubMed Web of Science ®Google Scholar
• Türk M, Carneiro-Leão L, Kolkhir P, et al. How to treat patients with chronic spontaneous urticaria with omalizumab: questions and answers. J Allergy Clin Immunol Pract. 2020;8(1):113–124. doi: 10.1016/j.jaip.2019.07.021.
   PubMed Web of Science ®Google Scholar
• Kolkhir P, Borzova E, Grattan C, et al. Autoimmune comorbidity in chronic spontaneous urticaria: a systematic review. Autoimmun Rev. 2017;16(12):1196–1208. doi: 10.1016/j.autrev.2017.10.003.
   PubMed Web of Science ®Google Scholar
• Kolkhir P, Metz M, Altrichter S, et al. Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: a systematic review. Allergy. 2017;72(10):1440–1460. doi: 10.1111/all.13182.
   PubMed Web of Science ®Google Scholar
• Maurer M, Staubach P, Raap U, et al. H1-antihistamine-refractory chronic spontaneous urticaria: it’s worse than we thought - first results of the multicenter real-life AWARE study. Clin Exp Allergy. 2017;47(5):684–692. doi: 10.1111/cea.12900.
   PubMed Web of Science ®Google Scholar
• Shalom G, Magen E, Babaev M, et al. Chronic urticaria and the metabolic syndrome: a cross-sectional community-based study of 11 261 patients. J Eur Acad Dermatol Venereol. 2018;32(2):276–281. doi: 10.1111/jdv.14548.
   PubMed Web of Science ®Google Scholar
• Goldstein S, Gabriel S, Kianifard F, et al. Clinical features of adolescents with chronic idiopathic or spontaneous urticaria: review of omalizumab clinical trials. Ann Allergy Asthma Immunol. 2017;118(4):500–504. doi: 10.1016/j.anai.2017.02.003.
   PubMed Web of Science ®Google Scholar
• Martina E, Damiani G, Grieco T, et al. It is never too late to treat chronic spontaneous urticaria with omalizumab: real-life data from a multicenter observational study focusing on elderly patients. Dermatol Ther. 2021;34(2):e14841. doi: 10.1111/dth.14841.
   PubMed Web of Science ®Google Scholar
• Bauersachs R, Zeymer U, Brière JB, et al. Burden of coronary artery disease and peripheral artery disease: a literature review. Cardiovasc Ther. 2019;2019:8295054–8295059. doi: 10.1155/2019/8295054.
   PubMed Web of Science ®Google Scholar
• Staubach P, Dechene M, Metz M, et al. High prevalence of mental disorders and emotional distress in patients with chronic spontaneous urticaria. Acta Derm Venereol. 2011;91(5):557–561. doi: 10.2340/00015555-1109.
   PubMed Web of Science ®Google Scholar